Veracyte

C2i Genomics, Inc. is a biotechnology company that specializes in whole genome analysis solutions aimed at monitoring tumor recurrence in post-resection cancer patients. Founded in 2019 and based in New York with a research and development center in Haifa, Israel, the company offers liquid biopsy services that detect subtle changes in tumor DNA to assess cancer recurrence and progression. Its technology supports a bio-platform approach applicable across various cancer types, enhancing the effectiveness of treatments such as surgery, chemotherapy, immunotherapy, and targeted therapies. Additionally, C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations, enabling healthcare professionals to monitor treatment responses and detect potential treatment failures or disease recurrence more effectively than traditional methods.

HalioDx designs and develops oncology diagnostics that analyze the immune contexture of tumors to inform prognosis and guide treatment decisions.

Decipher Biosciences, Inc. is a genomic information company focused on the development and commercialization of clinical tests for urologic cancers. The company specializes in providing genomic tests such as Decipher Prostate Biopsy, which analyzes tumor tissue to tailor treatment based on the metastatic potential of prostate cancer. Additionally, Decipher Bladder offers genomic subtyping for muscle-invasive bladder cancer, assisting healthcare providers in determining which patients may benefit from neoadjuvant chemotherapy before radical cystectomy. Founded in 2008 and headquartered in San Diego, California, Decipher Biosciences also operates a research and development center in Vancouver, Canada. The company is actively expanding its GRID database, which consists of over 70,000 whole transcriptome profiles, and collaborates with pharmaceutical companies to identify biomarkers for new therapeutic responses.

Allegro Diagnostics, founded in 2006 by Dr. Jerome Brody and Dr. Avrum Spira, is a molecular diagnostics company based in Maynard, Massachusetts. The firm specializes in the development and commercialization of advanced genomic tests aimed at diagnosing, staging, and guiding treatment for lung cancer and other lung diseases. Utilizing a proprietary molecular testing platform, Allegro analyzes specific changes in gene expression within airway epithelial cells to detect early signs of lung cancer, particularly in current and former smokers. This innovative approach provides healthcare professionals with essential diagnostic information, facilitating quicker diagnosis and more effective treatment options for patients.